Johnson & Johnson Lifescan
This article was originally published in The Gray Sheet
J&J division is sending users of SureStep over-the-counter blood glucose meters manufactured prior to August 1997 a warning sticker that reads: "Notice, Er 1 [readings] may mean a very high blood glucose. Check color chart on strip vial." The firm is instructing users to affix the sticker to existing SureStep systems (including those with serial numbers beginning L6000 through L7205) until a replacement meter is obtained free-of-charge by calling a toll free number. A letter describing the situation and including a SureStep reference guide also is being sent. The move is part of the firm's voluntary recall effort for a subset of SureStep devices, and comes in the midst of an FDA/California attorney general probe investigating, in part, whether the device gives an "Er 1" (Error 1) message if a patient's blood glucose level is 500 mg/dL or greater ("The Gray Sheet" April 13, p. 32). Users who obtain an Er 1 message should "compare the blue color dot on the test strip with the color chart on the back of the test strip bottle," J&J says in a June 4 release. "If the dot on the strip is as dark or darker than the darkest oval on the bottle's color chart, they likely have a very high blood glucose," and the user should immediately contact a health care professional...
You may also be interested in...
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.
In addition to our daily in-depth coverage of key regulatory events relating to the coronavirus pandemic, we’re bringing you selected brief insights into the impact on biopharma commercial activities.